Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

Universe Pharmaceuticals INC (NASDAQ: UPC) has announced that it will implement a dual-class share structure, effective February 13, 2026. This development follows the satisfaction of all conditions necessary for the change, aimed at providing the company with greater flexibility and strategic options in the capital markets. To facilitate this dual-class structure, Universe Pharmaceuticals amended its memorandum and articles of association, increasing its authorized capital to US$20,000, which will now be allocated into 1.8 billion class A ordinary shares and 200 million class B ordinary shares, both with a par value of US$0.00001 each.

The Class A Ordinary Shares are set to continue trading under the stock symbol "UPC" on the Nasdaq Capital Market, ensuring continuity for existing investors. Universe Pharmaceuticals operates out of Ji’an, Jiangxi, China, focusing on producing and distributing pharmaceutical products and traditional Chinese medicine, specifically catering to aging populations. The company's offerings include biomedical drugs, medical instruments, and dietary supplements from third-party manufacturers, reaching a broad market across 30 provinces in China.

This strategic shift to a dual-class share structure is viewed as a move to reinforce the company’s governance and control while enhancing market liquidity. However, as highlighted in the company's forward-looking statements, there remain inherent risks and uncertainties associated with this transition and the broader business operations. Universe Pharmaceuticals emphasizes that actual results could differ materially from its projections and encourages stakeholders to review additional risk factors detailed in its annual reports and filings with the U.S. Securities and Exchange Commission. For further inquiries, investors can contact Ms. Lin Yang, the Chief Financial Officer, via the provided email.

In light of Universe Pharmaceuticals INC's recent announcement regarding the implementation of a dual-class share structure effective February 13, 2026, investors should carefully evaluate the implications of this move on their investment strategy. This structural change, which is designed to enhance capital-raising capabilities while maintaining control within existing management, may fundamentally alter the company's governance dynamics.

The dual-class share structure typically empowers majority shareholders—often company founders or management—by giving them more voting rights per share. While this can facilitate long-term strategic planning without shareholder interference, it might concern potential investors about a lack of accountability and the alignment of management's interests with those of minority shareholders. Thus, discerning investors should weigh these governance considerations alongside financial indicators when assessing Universe Pharmaceuticals as an investment opportunity.

The Company specializes in producing and distributing traditional Chinese medicinal products aimed at the aging population, a demographic experiencing growth in China amidst an economic emphasis on healthcare and longevity. This market positioning bodes well for long-term revenue growth, particularly as the demand for elder care and wellness products continues to escalate.

However, potential investors should also consider the inherent market risks associated with the pharmaceuticals sector, particularly within China. Regulatory changes and competition from both domestic and international players could impact Universe Pharmaceuticals' market position and growth prospects.

As the shares continue to trade under the symbol "UPC" post-restructuring, it is crucial for investors to monitor trading volumes and price movements closely, especially in the initial days after the dual-class structure goes live. Observing how investor sentiment develops in response to this change will provide insights into the market's perception of the company's governance and growth trajectory. Overall, while the dual-class structure may pose risks, the underlying demand for its products could provide a favorable growth outlook if managed effectively.